Sangam Health Care Products Ltd

MD re-appointment

• Re-appointed Bhagat Reddy Dundumulla as Managing Director for five years from 05 Sep 2026.
• Subject to shareholders' approval at the ensuing AGM.
• Profile: 12 years’ experience in manufacturing IV sets and medical disposables.
• Not related to any other director.
• Shareholding: 200,000 shares.
• Not debarred by SEBI or other authorities.

Director re-appointment: Padma Ghanakota

• Recommendation for reappointment of Padma Ghanakota (DIN 07078176) who retires by rotation.
• Subject to approval by members at the AGM.

Meeting Details

• Date, time, and venue not disclosed in this chunk.

Dematerialisation processing and listing status

• Dematerialisation requests processed; securities mutilated and cancelled, depository registered owner updated within the stipulated time.
• Securities dematerialised are listed on the stock exchange where the earlier issues are listed.
• Certificate received for dematerialisation mutilated and cancelled; depository's name substituted as registered owner within 30 days.

FY26 results

• 📊 Revenue from operations fell 10% YoY to ₹1,123.33 lakh.
• 📊 Total income declined to ₹1,125.44 lakh from ₹1,248.07 lakh.
• 📊 PBT swung to a ₹47.39 lakh loss from ₹25.46 lakh profit.
• 📊 PAT fell to ₹5.33 lakh from ₹44.96 lakh, after deferred tax credit.
• 📊 Q4 FY26 revenue was ₹265.50 lakh, versus ₹258.11 lakh a year earlier.
• 📊 Q4 FY26 PAT was a ₹27.89 lakh loss, versus ₹18.76 lakh profit.
• 📊 Employee benefit expense rose to ₹328.68 lakh from ₹169.69 lakh.
• 📊 Other expenses increased to ₹277.90 lakh from ₹205.55 lakh.
• 📊 Finance cost remained low at ₹0.91 lakh for FY26.
• 📊 Basic and diluted EPS were ₹0.04 for FY26, versus ₹0.30 last year.

Balance sheet and cash

• 📊 Equity share capital stood at ₹1,486.07 lakh as of 31 March 2026.
• 📊 Borrowings were ₹615.27 lakh, with trade payables at ₹658.22 lakh.
• 📊 Cash and cash equivalents were ₹15.17 lakh at year-end.
• 📊 Trade receivables were ₹352.38 lakh and inventories ₹101.36 lakh.

Audit and reporting

• 📍 Statutory auditors issued an unmodified opinion on FY26 standalone results.
• 📍 Results were approved by the board on 29 May 2026.
• 📍 The company reported a single business segment.

Business model

• 🗒️ Sangam Health Care Products operates as a single-segment healthcare products company.
• 🗒️ The document does not break out product or geography revenue mix.

🗓️ Meeting Details

• Board meeting scheduled for February 13, 2026, at the company's registered office.

📊 Key Agenda Items

• Approval of unaudited financial results for the quarter ended December 31, 2025.
• Consideration of the Limited Review Report for the quarter ended December 31, 2025.